Proteins

Inhibitors

Deltasonamide 1 TFA

Cat. No.: HY-122641D CAS No.: 2235358-73-1 Molecular Formula: $C_{32}H_{40}ClF_{3}N_{6}O_{6}S_{2}$

Molecular Weight: 761.27

Phosphodiesterase (PDE) Target: Pathway: Metabolic Enzyme/Protease

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

H₂O: 200 mg/mL (262.72 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.3136 mL	6.5680 mL	13.1359 mL
	5 mM	0.2627 mL	1.3136 mL	2.6272 mL
	10 mM	0.1314 mL	0.6568 mL	1.3136 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description Deltasonamide 1 TFA is a PDE6 δ -KRas inhibitor. Deltasonamide 1 can inhibit PDE6 δ -KRas with a KD of 203 pM.

Deltasonamide 1 can be used for the research of tumors [1].

KD: 203 pM (PDE6 δ -KRas)^[1] IC₅₀ & Target

In Vitro Deltasonamide 1 can inhibit PDE6 δ -KRas with a K_D of 203 pM^[1].

Deltasonamide 1 binds to PDE6 δ with up to 7 hydrogen bonds, resulting in picomolar affinity^[1].

 $\label{eq:decomposition} \mbox{Deltasonamide 1 strongly reduces proliferation} \mbox{$^{[1]}$}.$

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	RTCA of hPDAC cell lines
Concentration:	0.375, 0.75, 1.5, 3, 6, 12 μΜ
Incubation Time:	60 h

Result:	Inhibited proliferation of human pancreatic cancer cell lines.

REFERENCES

[1]. Pablo Martín-Gago, et al. A PDE6 δ -KRas Inhibitor Chemotype With Up to Seven H-Bonds and Picomolar Affinity That Prevents Efficient Inhibitor Release by Arl2. Angew Chem Int Ed Engl. 2017 Feb 20;56(9):2423-2428.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com